These advancements, coupled with an alarming rise in the number of peptic ulcer cases have been instrumental in the robust growth of the global peptic ulcer drugs market. Increased government and private funding for drug development R&D and growing awareness regarding the disease and its treatment are expected to sustain this promising growth momentum.Peptic ulcers are primarily caused by a bacteria called Helicobacter pylori (H. pylori). Moreover, unregulated consumption of nonsteroidal anti-inflammatory medications (NSAIDs) also causes peptic ulcers.  NSAIDs are commonly referred to as painkillers including aspirin, ibuprofen, and naproxen sodium. The discovery of H. pylori bacteria that causes these ulcers has been a remarkable medical science breakthrough which is enabling the rapid development of viable treatment methods.

For More Industry Insight Read:

Increasing Geriatric Population to Maintain Strong Growth Trajectory of Peptic Ulcer Drugs Market

In the past decade, the occurrence of peptic ulcers has exploded at an alarming pace. Many factors are contributing to setting up this precedent. Increasing cases of stress, the growing infection rate of Helicobacter pylori (H. pylori), cancer prevalence, and drug-induced ulcers are the factors that boost the occurrence of peptic ulcers. Moreover, the growing adoption of unhealthy lifestyles and consumption of alcohol and tobacco are further contributing to this healthcare challenge. The geriatric population is particularly vulnerable to developing peptic ulcers as the peak incidence occurs at ages between 55 and 65 years. The global peptic ulcer drugs market is poised to grow in such a business environment.

Focused Drug Development R&D Efforts to Assist Long-term Growth of Peptic Ulcer Drugs Market

Amidst the incessant increment in the cases of peptic ulcers, several government healthcare bodies and pharmaceutical manufacturers are taking serious cognizance to combat the issue. Recent medical science breakthroughs in discovering the H. pylori bacteria have allowed healthcare professionals to treat the infection via advanced antibiotics. Triple therapy is often used and it comprises two antibiotics and a proton pump inhibitor. This is a first-line treatment and more advanced therapeutics are expected owing to robust pharmaceutical R&D initiatives and supportive regulations. These promising innovations are expected to drive the global peptic ulcer drugs market to fructuous business outcomes in the coming years.

North America’s Peptic Ulcer Drugs Market to Dominate with Increasing Pain Killer Usage, and Healthcare Expenditures

The presence of robust healthcare infrastructure, high healthcare expenditure per capita, and concentration of several major market players are auguring well for the peptic ulcer drugs industry in North America. Key regional economies such as the USA are showcasing increased incidences of peptic ulcer cases. Moreover, the focused research and development efforts to develop more innovative and effective drugs are sustaining the market upsurge. Unregulated usage of nonsteroidal anti-inflammatory medications (NSAIDs) is also emerging as a major contributor to growing peptic ulcer cases. All these factors are cementing North America as the leading regional peptic ulcer drugs industry.

Leading Market Players

The most active players in the global peptic ulcer drugs industry include Pfizer Inc., AstraZeneca plc, Cadila Healthcare Ltd., GlaxoSmithKline plc., Abbvie Inc., Boehringer Ingelheim GmbH, Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical, Eisai Co. Ltd., and Yuhan Corporation.

Get Sample/Toc Copy Of Report:

Latest Trending Reports:

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness. 


Fairfield Market Research  

London, UK 

UK +44 (0)20 30025888     

USA (Toll-free) +1 (844) 3829746  



Follow Us: LinkedIn